Reshma Rangwala

CIK: 0001825322

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)6 (54.5%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (45.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KPTI

Karyopharm Therapeutics Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

KPTI
Karyopharm Therapeutics Inc.
May 14, 2026
Sale(S)
Direct
408 shares at avg. $9.50$4K
KPTI
Karyopharm Therapeutics Inc.
May 13, 2026
Award(A)
Direct
947 shares-
KPTI
Karyopharm Therapeutics Inc.
Apr 21, 2026
Sale(S)
Direct
449 shares at avg. $8.94$4K
KPTI
Karyopharm Therapeutics Inc.
Mar 2, 2026
Sale(S)
Direct
5.1K shares at avg. $9.41$48K
KPTI
Karyopharm Therapeutics Inc.
Jan 31, 2026
Award(A)
Direct
32.4K shares-
KPTI
Karyopharm Therapeutics Inc.
Sep 15, 2025
Sale(S)
Direct
408 shares at avg. $6.43$3K
KPTI
Karyopharm Therapeutics Inc.
Sep 12, 2025
Award(A)
Direct
945 shares-
KPTI
Karyopharm Therapeutics Inc.
Apr 23, 2025
Sale(S)
Direct
419 shares at avg. $6.17$3K
KPTI
Karyopharm Therapeutics Inc.
Mar 4, 2025
Sale(S)
Direct
3.6K shares at avg. $6.29$23K
KPTI
Karyopharm Therapeutics Inc.
Feb 28, 2025
Award(A)
Direct
4.6K shares-
KPTI
Karyopharm Therapeutics Inc.
Feb 28, 2025
Award(A)
Direct
5.4K shares-

		Type	Shares	Price		Ownership
May 14, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	408	$9.50	$3,876	Direct
May 13, 2026	KPTI Karyopharm Therapeutics Inc.	Award(A)	947	-	$0	Direct
Apr 21, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	449	$8.94	$4,014	Direct
Mar 2, 2026	KPTI Karyopharm Therapeutics Inc.	Sale(S)	5,066	$9.41	$47,669	Direct
Jan 31, 2026	KPTI Karyopharm Therapeutics Inc.	Award(A)	32,415	-	$0	Direct
Sep 15, 2025	KPTI Karyopharm Therapeutics Inc.	Sale(S)	408	$6.43	$2,623	Direct
Sep 12, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	945	-	-	Direct
Apr 23, 2025	KPTI Karyopharm Therapeutics Inc.	Sale(S)	419	$6.17	$2,585	Direct
Mar 4, 2025	KPTI Karyopharm Therapeutics Inc.	Sale(S)	3,587	$6.29	$22,562	Direct
Feb 28, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	4,583	-	-	Direct
Feb 28, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A)	5,416	-	-	Direct

1-11 of 11 transactions

About Rangwala Reshma

Rangwala Reshma (SEC CIK 0001825322) files insider reports with the SEC as EVP & Chief Medical Officer of Karyopharm Therapeutics Inc. (KPTI).

Signal8 holds 8 ownership filings by Rangwala Reshma, all Form 4s, filed between Mar 4, 2025 and May 15, 2026. Those filings report 11 transactions, from Feb 28, 2025 to May 14, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Rangwala Reshma's filings is in NEWTON, MA.

Recent filings by Rangwala Reshma

May 14, 2026: Open-market sale of KPTI shares (Form 4, code S).
May 13, 2026: Grant or award of KPTI shares (Form 4, code A).
Apr 21, 2026: Open-market sale of KPTI shares (Form 4, code S).
Mar 2, 2026: Open-market sale of KPTI shares (Form 4, code S).
Jan 31, 2026: Grant or award of KPTI shares (Form 4, code A).

Other insiders filing for Karyopharm Therapeutics Inc. (KPTI)

Abate Kristin, Chief Accounting Officer
Poulton Stuart, EVP, Chief Development Officer
Oliger Christy J., Director
PAKIANATHAN DEEPIKA, Director
Schor Chen, Director
Su Zhen, Director

How to read Form 4 transaction codes